Harvard Bioscience Inc (HBIO)
2.225
+0.06
(+3.01%)
USD |
NASDAQ |
Nov 22, 11:06
Harvard Bioscience Enterprise Value: 127.50M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 127.50M |
| November 20, 2024 | 127.50M |
| November 19, 2024 | 122.70M |
| November 18, 2024 | 127.06M |
| November 15, 2024 | 126.63M |
| November 14, 2024 | 133.17M |
| November 13, 2024 | 127.94M |
| November 12, 2024 | 132.73M |
| November 11, 2024 | 140.15M |
| November 08, 2024 | 145.38M |
| November 07, 2024 | 137.53M |
| November 06, 2024 | 156.29M |
| November 05, 2024 | 137.53M |
| November 04, 2024 | 136.66M |
| November 01, 2024 | 137.97M |
| October 31, 2024 | 135.79M |
| October 30, 2024 | 140.15M |
| October 29, 2024 | 140.15M |
| October 28, 2024 | 138.84M |
| October 25, 2024 | 134.48M |
| October 24, 2024 | 135.35M |
| October 23, 2024 | 136.22M |
| October 22, 2024 | 137.97M |
| October 21, 2024 | 136.66M |
| October 18, 2024 | 141.02M |
| Date | Value |
|---|---|
| October 17, 2024 | 137.53M |
| October 16, 2024 | 139.71M |
| October 15, 2024 | 140.15M |
| October 14, 2024 | 141.89M |
| October 11, 2024 | 143.64M |
| October 10, 2024 | 134.48M |
| October 09, 2024 | 136.66M |
| October 08, 2024 | 137.97M |
| October 07, 2024 | 137.97M |
| October 04, 2024 | 137.97M |
| October 03, 2024 | 140.59M |
| October 02, 2024 | 144.95M |
| October 01, 2024 | 144.08M |
| September 30, 2024 | 150.62M |
| September 27, 2024 | 150.25M |
| September 26, 2024 | 147.64M |
| September 25, 2024 | 147.64M |
| September 24, 2024 | 149.38M |
| September 23, 2024 | 146.76M |
| September 20, 2024 | 151.56M |
| September 19, 2024 | 152.87M |
| September 18, 2024 | 152.87M |
| September 17, 2024 | 159.85M |
| September 16, 2024 | 159.41M |
| September 13, 2024 | 157.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
99.94M
Minimum
Mar 19 2020
382.17M
Maximum
Aug 12 2021
217.66M
Average
201.49M
Median
May 11 2022
Enterprise Value Benchmarks
| Bruker Corp | 10.71B |
| Azenta Inc | 1.613B |
| Bionano Genomics Inc | 14.35M |
| Akoya Biosciences Inc | 145.08M |
| Singular Genomics Systems Inc | -53.66M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.802M |
| Revenue (Quarterly) | 21.97M |
| Total Expenses (Quarterly) | 23.66M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 58.10% |
| Profit Margin (Quarterly) | -21.86% |
| Earnings Yield | -14.83% |
| Normalized Earnings Yield | -12.69 |